Using LMS-Liver makes comparison studies less tedious for radiologists and ensures the oncologists and patients that such studies are carried out properly.
Clinical Trials
A large number of clinical trials is being undertaken to assess candidate drugs for cancer treatment and this number has increased drastically over the last years.
Imaging has a key role in clinical trials to evaluate candidate drugs effectiveness and imaging bio-markers are routinely used as secondary end points in drug trials. Very efficient and innovative imaging techniques - both morphological and functional - exist. They provide relevant information on candidate drugs effectiveness and are currently used during phase II and phase III trials.
In addition, international criteria such as RECIST (Response Evaluation Criteria in Solid Tumors) are well defined and commonly used to evaluate imaging endpoints response to therapy based on target lesion diameter change.
MEDIAN Lesion Management Solutions can optimize the utilization of images in multicentric clinical trials by :
- Automatically quantifying the evolution of target lesions in clinical trials
- Automatically generating RECIST reports
- Standardizing the process across all trial participants
- Storing all information on a centralized data management system
RECIST Reports
RECIST Report
